These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35209950)

  • 1. DrABC: deep learning accurately predicts germline pathogenic mutation status in breast cancer patients based on phenotype data.
    Liu J; Zhao H; Zheng Y; Dong L; Zhao S; Huang Y; Huang S; Qian T; Zou J; Liu S; Li J; Yan Z; Li Y; Zhang S; Huang X; Wang W; Li Y; Wang J; Ming Y; Li X; Xing Z; Qin L; Zhao Z; Jia Z; Li J; Liu G; Zhang M; Feng K; Wu J; Zhang J; Yang Y; Wu Z; Liu Z; Ying J; Wang X; Su J; Wang X; Wu N
    Genome Med; 2022 Feb; 14(1):21. PubMed ID: 35209950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
    Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
    Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
    J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
    Yadav S; Hu C; Hart SN; Boddicker N; Polley EC; Na J; Gnanaolivu R; Lee KY; Lindstrom T; Armasu S; Fitz-Gibbon P; Ghosh K; Stan DL; Pruthi S; Neal L; Sandhu N; Rhodes DJ; Klassen C; Peethambaram PP; Haddad TC; Olson JE; Hoskin TL; Goetz MP; Domchek SM; Boughey JC; Ruddy KJ; Couch FJ
    J Clin Oncol; 2020 May; 38(13):1409-1418. PubMed ID: 32125938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
    Hung FH; Wang YA; Jian JW; Peng HP; Hsieh LL; Hung CF; Yang MM; Yang AS
    Sci Rep; 2019 Jul; 9(1):10229. PubMed ID: 31308460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of genetic predisposition to molecular subtypes of breast cancer in Brazilian patients.
    Paixão D; Torrezan GT; Santiago KM; Formiga MN; Ahuno ST; Dias-Neto E; Tojal da Silva I; Foulkes WD; Polak P; Carraro DM
    Front Oncol; 2022; 12():976959. PubMed ID: 36119527
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting BRCA1 and BRCA2 gene mutation carriers: comparison of PENN II model to previous study.
    Lindor NM; Johnson KJ; Harvey H; Shane Pankratz V; Domchek SM; Hunt K; Wilson M; Cathie Smith M; Couch F
    Fam Cancer; 2010 Dec; 9(4):495-502. PubMed ID: 20512419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [BRCA2 Mutation Profile in a Proband with Hereditary Breast and Ovarian Cancer-Two Germline Pathogenic Variants Aligned in the Cis Position].
    Yukisawa S; Kakinuma T; Yotsumoto J; Kawakami K; Furukawa J; Shinozaki H
    Gan To Kagaku Ryoho; 2023 Oct; 50(10):1089-1091. PubMed ID: 38035841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
    Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
    Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Accuracy of Risk Prediction Models for Breast Cancer and
    Kenan ES; Friger M; Shochat-Bigon D; Schayek H; Bernstein-Molho R; Friedman E
    Anticancer Res; 2018 Aug; 38(8):4557-4563. PubMed ID: 30061222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimization of prediction methods for risk assessment of pathogenic germline variants in the Japanese population.
    Senda N; Kawaguchi-Sakita N; Kawashima M; Inagaki-Kawata Y; Yoshida K; Takada M; Kataoka M; Torii M; Nishimura T; Kawaguchi K; Suzuki E; Kataoka Y; Matsumoto Y; Yoshibayashi H; Yamagami K; Tsuyuki S; Takahara S; Yamauchi A; Shinkura N; Kato H; Moriguchi Y; Okamura R; Kan N; Suwa H; Sakata S; Mashima S; Yotsumoto F; Tachibana T; Tanaka M; Togashi K; Haga H; Yamada T; Kosugi S; Inamoto T; Sugimoto M; Ogawa S; Toi M
    Cancer Sci; 2021 Aug; 112(8):3338-3348. PubMed ID: 34036661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Distinct Performances of Ultrasound, Mammograms, and MRI in Detecting Breast Cancer in Patients With Germline Pathogenic Variants in Cancer Predisposition Genes.
    Liu J; Wang X; Dong L; Huang X; Zhao H; Li J; Huang S; Yuan P; Wang W; Wang J; Xing Z; Jia Z; Ming Y; Li X; Qin L; Liu G; Wu J; Li Y; Zhang M; Feng K; Ying J; Wang X
    Front Oncol; 2021; 11():710156. PubMed ID: 34336698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Germline mutation in DNA-repair genes is associated with poor survival in BRCA1/2-negative breast cancer patients.
    Fan Z; Hu L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
    Cancer Sci; 2019 Oct; 110(10):3368-3374. PubMed ID: 31432574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between germline pathogenic variants and breast cancer risk in Japanese women: The HERPACC study.
    Kasugai Y; Kohmoto T; Taniyama Y; Koyanagi YN; Usui Y; Iwase M; Oze I; Yamaguchi R; Ito H; Imoto I; Matsuo K
    Cancer Sci; 2022 Apr; 113(4):1451-1462. PubMed ID: 35218119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of pathogenic germline variants in BRCA1, BRCA2, PALB2, CHEK2 and TP53 in ductal carcinoma in situ diagnosed in women under the age of 50 years.
    Petridis C; Arora I; Shah V; Megalios A; Moss C; Mera A; Clifford A; Gillett C; Pinder SE; Tomlinson I; Roylance R; Simpson MA; Sawyer EJ
    Breast Cancer Res; 2019 May; 21(1):58. PubMed ID: 31060593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.